Eli Lilly's retatrutide, a next-generation weight-loss therapy, showed significant efficacy in clinical trials, driving substantial weight loss and improving related conditions like sleep apnea and knee pain. This strong performance positions it as a potential successor to current GLP-1s, creating a new competitive dynamic in the booming obesity drug market.